|Author(s)/Faculty: Judy E. Kim, MD; Rishi P. Singh, MD|
|Release Date: 3/8/2022||Expiration Date: 3/7/2023|
|Credit Type: CME / CME with ABO Continuing Certification ||Number of Credits: 0.5|
|Content Type: Lecture||Provider: |
|Significant visual and anatomic improvements through the integration of intravitreal anti-vascular endothelial growth factor (VEGF) therapies are well reported in the management of retinal and choroidal vascular diseases. However, there is still a proportion of patients who do not respond or have a suboptimal response to current anti-VEGF therapies. Treatments affecting alternative pathways involved in increased vascular permeability and abnormal angiogenesis, such as the angiopoietin/Tie2 pathway, are currently being assessed for efficacy and durability in clinical studies and have the potential to improve treatment response. In this CME activity, experts in the field summarize how angiopoietins influence vascular stability and instability in normal eyes as well as in retinal and choroidal vascular diseases. They also assess the latest clinical data regarding emerging injectable therapies that act on the Tie2 pathway to improve visual outcomes for these patients.